ChipAgents Raises Oversubscribed $21M Series A to Redefine AI for Chip Design
21.10.2025 16:30:00 CEST | Business Wire | Press Release
Today ChipAgents, the agentic AI platform transforming chip design and verification, announced the close of a $21 million Series A funding round, bringing the total fundraise to $24 million to date. This latest round closed with Bessemer Venture Partners, with strategic backing from Micron, MediaTek, Ericsson, and additional top semiconductor companies. Also participating in the round are notable angels including new advisors, Wally Rhines, Raúl Camposano,and Jack Harding, and existing support by ScOp Venture Capital (Ivan Bercovich) and Amino Capital, fueling the company’s expansion of product development, customer acquisition, and strategic industry partnerships.
ChipAgents’ mission is to bring the power of AI to the heart of chip design and verification. Every engineer should be empowered with tools that make the most complex aspects of hardware development faster, more intuitive, and dramatically more productive. Chips are the foundation of our digital world, yet the process of building and verifying them remains slow, costly, and labor-intensive. By rethinking workflows with AI, ChipAgents shortens design cycles, accelerates innovation, and helps semiconductor companies deliver breakthroughs that will shape the next decade of technology.
“Electronic design automation (EDA) has powered decades of semiconductor progress, but today’s engineers still struggle with fragmented toolchains, steep costs, and workflows that haven’t kept pace with rapidly growing chip complexity,” said Founder and CEO, Professor William Wang. “As designs scale, productivity gains have slowed and verification remains highly manual. Our vision is to change that. With ChipAgents, we’re introducing a unified agentic AI platform designed to automate routine tasks, accelerate design and verification, and enable AI-native workflows that help engineers focus on innovation rather than repetitive effort.”
Building on the momentum of its seed round, ChipAgents saw a 6,377% surge in monthly usage in the first half of 2025, leveraging agentic AI to accelerate RTL code generation, testbench creation, debugging, and verification through intuitive, language-based commands. The result: expedited time-to-market, cost reductions, and a redefined benchmark for productivity in chip development. Across independent teams, ChipAgents achieves 80% higher productivity in verification compared to industry practices and is deployed at 50 leading semiconductor companies, showcasing its ability to deliver real-world value at scale. The company sees a 50x YoY growth in annual recurring revenue (ARR) in the beginning of its second year.
"ChipAgents has demonstrated itself as having the best product in the market that does AI-powered RTL design, debugging, and verification for chip developers,” said Lance Co Ting Keh, Venture Partner at Bessemer Venture Partners. “We’re impressed by Professor William Wang’s deep technical expertise and the exceptional team of AI and hardware design experts he’s assembled. ChipAgents’ agentic approach to AI chip design integrates seamlessly across the entire chip design workflow, bringing together disparate EDA tools from spec ingestion to waveform analysis, which we believe is the right way to tackle this complex, multi-step process. The feedback from customers and technical experts validates that ChipAgents isn't just automating individual tasks, but creating a true force multiplier for hardware design engineers.”
“Micron Ventures supports bold AI companies led by visionary founders developing transformative technologies. ChipAgents’ mission to reinvent chip design through AI agents aligns closely with our focus, especially as chipmakers require faster, more intelligent design solutions to meet the accelerating demands of AI hardware. At this pivotal inflection point, ChipAgents presents a high-impact opportunity to invest in the future of semiconductor development,” said Henry Huang, Investment Director at Micron Ventures.
ChipAgents has also bolstered its leadership team with the formation of a world-class advisory board composed of several of the semiconductor industry’s most distinguished veterans. The new board includes Wally Rhines, former CEO of Mentor Graphics (now Siemens EDA); Raúl Camposano, former CTO of Synopsys; Jack Harding, former CEO of Cadence; and Erez Tsur, former CEO of Cadence Israel. Collectively, with additional guidance from founding advisor, Dr. John Bowers, these silicon luminaries bring decades of experience in building and scaling the very companies that have defined the EDA landscape.
"ChipAgents demonstrates the major impact that AI can have on the full range of integrated circuit design tasks,” said Wally Rhines. “I’ve met with three major semiconductor companies that have done competitive assessments of AI-based design solutions, and ChipAgents is the number one choice at all three.”
"ChipAgents is pioneering a new era in semiconductor design, where AI and engineering expertise converge for smarter solutions. The implications for the semiconductor industry are nothing short of transformative, and I’m excited to support their mission,” said Raúl Camposano.
Book a demo with ChipAgents to learn more about the agentic AI EDA platform, and check out the open positions to join the pioneering team.
About ChipAgents
ChipAgents is a cutting-edge AI startup delivering generative, agentic solutions for chip design and verification. Its flagship product transforms how hardware companies define, validate, and refine RTL code, simplifying complex workflows while driving unmatched productivity and accuracy. For more information, visit ChipAgents.ai or follow us on LinkedIn and Twitter/X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251021677325/en/
Contacts
Media Contact:
press@alphadesign.ai
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press Release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press Release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press Release
Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performance information are continuously updating the DPP and seamlessly exchanged with DPP applications. Data4Industry-X builds on European standards such as the G
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press Release
Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performance information are continuously updating the DPP and seamlessly exchanged with DPP applications. Data4Industry-X builds on European standards such as the G
Saildrone Unveils Spectre, a New Class of High-Speed Unmanned Surface Vessel for Naval Operations20.4.2026 14:00:00 CEST | Press Release
Saildrone, the world leader and most experienced operator of unmanned surface vehicles (USVs), today released the design of the Saildrone Spectre, the culmination of two years of intense design work, leveraging over 10 years of operational USV experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260420620393/en/ Two Saildrone Spectre variants are built around different mission needs: Spectre Silent Endurance (right) uses wing assist for extreme endurance and silent propulsion. Spectre Stealth Strike (left) meets all mUSV requirements. At 52 meters (170 feet) long, weighing 250 tonnes, and capable of up to 30 knots, Spectre is the largest, fastest, and most capable Saildrone platform to date. Spectre is optimized for anti-submarine warfare (ASW) operations, a mission set that demands extreme endurance and an ultra-quiet acoustic signature. Spectre achieves this by leveraging the proven endurance, reliability, and silent
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom